← Evidence map

ArticleEsophagus : official journal of the Japan Esophageal Society2026

Correction: First-line pembrolizumab plus chemotherapy versus chemotherapy alone for advanced esophageal cancer: 5-year extended follow-up in the Japanese subgroup of KEYNOTE-590.

Ken Kato et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Full record →Abstract, authors, funding and every citing paper · PMID 42830372